Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Leukemia, Myeloid, Acute × fludarabine × Clear all

Phase

Phase 2 82 Phase 1 59 Phase 1/2 29 Phase 3 22 Phase NA 7 Phase 4 4 Phase EARLY_PHASE1 2 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Mantle-Cell 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Older Patients 1 Myasthenia Gravis 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, B-Cell 1 Autoimmune Diseases 1

Interventions

Cytarabine 11 venetoclax 9 Decitabine 7 Daunorubicin 7 Azacitidine 7 Cyclophosphamide 6 Busulfan 6 fludarabine phosphate 5 Idarubicin 5 Gemtuzumab 5 Thiotepa 3 Stem Cell Transplantation 3 Cyclosporine 3 vosaroxin 2 Tretinoin 2 Sorafenib 2 Radiotherapy 2 Methylprednisolone 2 Methotrexate 2 Melphalan 2 Injections 2 Filgrastim 2 Etoposide 2 Cladribine 2 CPX-351 2 Antilymphocyte Serum 2 Abatacept 2 vedolizumab 1 uproleselan 1 tipifarnib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04217278 2023-05-10

COSI

University of Birmingham

Phase 2/3 Unknown

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡